BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sabnis RW. Heterocyclic Compounds as Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia (AML). ACS Med Chem Lett 2021;12:1641-2. [PMID: 34795852 DOI: 10.1021/acsmedchemlett.1c00532] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Sainas S, Giorgis M, Circosta P, Poli G, Alberti M, Passoni A, Gaidano V, Pippione AC, Vitale N, Bonanni D, Rolando B, Cignetti A, Ramondetti C, Lanno A, Ferraris DM, Canepa B, Buccinnà B, Piccinini M, Rizzi M, Saglio G, Al-Karadaghi S, Boschi D, Miggiano R, Tuccinardi T, Lolli ML. Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: SAR of the Aryloxyaryl Moiety. J Med Chem 2022. [PMID: 36162075 DOI: 10.1021/acs.jmedchem.2c00496] [Reference Citation Analysis]